Repositioning Candidate Details
| Candidate ID: | R0028 |
| Source ID: | DB00098 |
| Source Type: | approved |
| Compound Type: | biotech |
| Compound Name: | Antithymocyte immunoglobulin (rabbit) |
| Synonyms: | Anti-human thymocyte immunoglobulin, rabbit; Anti-T-lymphocyte immune globulin, rabbit; Anti-thymocyte globulin (rabbit); Anti-thymocyte globulin rabbit; Antithymocyte immunoglobulin; Lapine T-lymphocyte immune globulin; Rabbit anti-human thymocyte globulin; Rabbit anti-human thymocyte globulin (rATG); Rabbit anti-human thymocyte immunoglobulin; Rabbit anti-thymocyte immunoglobulin; Rabbit antithymocyte globulin; Rabbit ATG; rATG; Thymoglobulin; Thymoglobuline |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells. |
| CAS Number: | 308067-60-9 |
| Molecular Weight: | |
| DrugBank Indication: | For prevention of renal transplant rejection |
| DrugBank Pharmacology: | Antithymocyte Globulin (ATG) is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. ATG is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation. ATG reduces the host immune response against tissue transplants or organ allografts. |
| DrugBank MoA: | Binds to multiple, T-cell specific antigens leading to T-lymphocyte cell death via complement mediated cytotoxicity or apoptosis. |
| Targets: | T-cell surface glycoprotein CD1a inhibitor; Major histocompatibility complex class I-related gene protein antagonist; Integrin alpha-L; T-lymphocyte activation antigen CD86 binder; Low affinity immunoglobulin gamma Fc region receptor II-b; T-cell surface glycoprotein CD4; Integrin beta-1; Integrin alpha-V; Integrin beta-3 |
| Inclusion Criteria: | Therapeutic strategy associated |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|